Suchergebnisse

Management im Gesundheitswesen boomt: In vielen Bereichen des Gesundheitswesens besteht ein großer Bedarf an Fach- und Führungskräften im Managementbereich, die über eine interdisziplinäre Ausrichtung verfügen und mit den speziellen institutionellen Gegebenheiten des Gesundheitswesens vertraut sind. So ist - in Praxis und Theorie - die Zeit reif für dieses umfassende neue Lehrbuch. Es stellt alle wichtigen Aspekte des Managements von Einrichtungen im Gesundheitswesen umfassend dar. Didaktisch aufbereitet folgen alle Themenblöcke einer einheitlichen Struktur mit einer Einführung zu den gesetzlichen, strukturellen und methodischen Grundlagen. Anschließend gehen die Autoren jeweils ausführlich auf die speziellen Anforderungen und ihre praktische Umsetzung in folgenden Sektoren des Gesundheitswesens ein: gesetzliche und private Krankenversicherungen, Krankenhäuser, Arztpraxen und Ärztenetze, Arzneimittelindustrie und Netzwerke zur integrierten Versorgung. Zusätzliches Plus: Fallstudien vertiefen wichtige Aspekte der praktischen Anwendung und eignen sich gut als Material für den Unterricht bzw. das Selbststudium. Geschrieben für:Praktiker und zukünftige Entscheider in Krankenhäusern, Arztpraxen, Krankenkassen und in der Arzneimittelindustrie sowie Studierende der Wirtschaftswissenschaften, der Medizin und Teilnehmer von postgradualen Studiengängen Schlagworte: Gesundheitsleistungen Gesundheitsmanagement Gesundheitswesen Leistungsmanagement

During the summer of 2005, the Big Three U.S. automobile manufacturers offered a customer promotion that allowed customers to buy new cars at the discounted price formerly offered only to employees. The initial months of the promotion were record sales months for each of the Big Three firms, suggesting that customers thought that the prices offered during the promotions were particularly attractive. In fact, such large rebates had been available before the employee discount promotion that many customers paid higher prices following the introduction of the promotions than they would have in the weeks just before. We hypothesize that the complex nature of auto prices, the fact that prices are negotiated rather than posted, and the fact that buyers do not participate frequently in the market leads customers to rely on "price cues" in evaluating how good current prices are. We argue that the employee discount pricing promotions were price cues, and that customers responded to the promotions as a signal that prices were discounted.

Many environmental regulations encourage the use of "clean" inputs. When the suppliers of such an input have market power, environmental regulation will affect not only the quantity of the input used but also its price. We investigate the effect of the Title IV emissions trading program for sulfur dioxide on the market for low‐sulfur coal. We find that the two railroads transporting coal were able to price discriminate on the basis of environmental regulation and geographic location. Delivered prices rose for plants in the trading program relative to other plants, and by more at plants near a low‐sulfur coal source.

Political background As a German novelty, the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; IGWiG ) was established in 2004 to, among other tasks, evaluate the benefit of pharmaceuticals. In this context it is of importance that patented pharmaceuticals are only excluded from the reference pricing system if they offer a therapeutic improvement. The institute is commissioned by the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA ) or by the Ministry of Health and Social Security. The German policy objective expressed by the latest health care reform (Gesetz zur Modernisierung der Gesetzlichen Krankenversicherung, GMG ) is to base decisions on a scientific assessment of pharmaceuticals in comparison to already available treatments. However, procedures and methods are still to be established.Research questions and methods This health technology assessment (HTA) report was commissioned by the German Agency for HTA at the Institute for Medical Documentation and Information (DAHTA@DIMDI). It analysed criteria, procedures, and methods of comparative drug assessment in other EU-/OECD-countries. The research question was the following: How do national public institutions compare medicines in connection with pharmaceutical regulation, i.e. licensing, reimbursement and pricing of drugs? Institutions as well as documents concerning comparative drug evaluation (e.g. regulations, guidelines) were identified through internet, systematic literature, and hand searches. Publications were selected according to pre-defined inclusion and exclusion criteria. Documents were analysed in a qualitative matter following an analytic framework that had been developed in advance. Results were summarised narratively and presented in evidence tables.Results and discussion Currently licensing agencies do not systematically assess a new drug's added value for patients and society. This is why many countries made post-licensing evaluation of pharmaceuticals a ...

We investigate whether car buyers are myopic about future fuel costs. We estimate the effect of gasoline prices on short-run equilibrium prices of cars of different fuel economies. We then compare the implied changes in willingness-to-pay to the associated changes in expected future gasoline costs for cars of different fuel economies in order to calculate implicit discount rates. Using different assumptions about annual mileage, survival rates, and demand elasticities, we calculate a range of implicit discount rates similar to the range of interest rates paid by car buyers who borrow. We interpret this as showing little evidence of consumer myopia. (JEL D12, H25, L11, L62, L71, L81)